<DOC>
	<DOC>NCT00095277</DOC>
	<brief_summary>The purpose of this trial is to demonstrate benefit with respect to hematopoietic response in subjects with anemia of cancer randomized to Darbepoetin Alfa once every 4 weeks.</brief_summary>
	<brief_title>Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Eligibility Criteria: Subjects with nonmyeloid malignancies Subjects can not be on chemotherapy Anemia of cancer Eastern Cooperative Oncology Group (ECOG) status of 0 to 2 Hemoglobin less than or equal to 11.0 g/dL Adequate renal and liver function Written informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>non-myeloid malignancies</keyword>
	<keyword>myeloma</keyword>
	<keyword>Anemia of Cancer</keyword>
</DOC>